A manual has been developed regarding accelerometer downloading and uploading procedures, data storage, and data cleaning treatment protocols, and automated data extraction procedures are currently being developed.
The current study, as a pilot project for the Right Drug, Right Dose, Right Time Using Genomic Data to Individualize Treatment Protocol, was designed to evaluate the impact of preemptive PGx and to optimize the workflow in the clinic setting.
To report the design and implementation of the Right Drug, Right Dose, Right Time Using Genomic Data to Individualize Treatment protocol that was developed to test the concept that prescribers can deliver genome-guided therapy at the point of care by using preemptive pharmacogenomics (PGx) data and clinical decision support (CDS) integrated into the electronic medical record (EMR).
Data on the treatment protocol have been reported elsewhere (Bokemeyer et al, 1998).
To obtain further information on the usefulness of our treatment protocol, data of the 15 patients were entered into the nomogram, and we found that predicted pathological complete response rate for our patients was 12%, whereas the actual rate observed was 6.6%.
None of the studies used PAC-specific data to drive a treatment protocol that is known to improve outcome.
These plasma IDS activities returned to the levels measured in the untreated MPSII mice 72 h after the last injections of each treatment protocol (data not shown).
However, at the present time we are unable to confirm this new treatment protocol since data on long-term outcome are still missing.
Institutional review boards at Harvard and the individual clinics (Jos University Teaching Hospital, Nigerian Institute of Medical Research, 68 Military Hospital, and University of Maiduguri Teaching Hospital) approved the treatment protocol and data collection forms.
The materials, experimental setup, test protocol, and data treatment are explained thoroughly to allow reproduction.
